{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T13:15:13Z","timestamp":1770815713805,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2009,4,3]],"date-time":"2009-04-03T00:00:00Z","timestamp":1238716800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Bone Miner Metab"],"published-print":{"date-parts":[[2009,7]]},"DOI":"10.1007\/s00774-009-0057-7","type":"journal-article","created":{"date-parts":[[2009,4,2]],"date-time":"2009-04-02T04:35:29Z","timestamp":1238646929000},"page":"471-478","source":"Crossref","is-referenced-by-count":19,"title":["The efficacy and tolerability of once-weekly alendronate 70\u00a0mg on bone mineral density and bone turnover markers in postmenopausal Chinese women with osteoporosis"],"prefix":"10.1007","volume":"27","author":[{"given":"Yuxiang","family":"Yan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanmin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianli","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bangyao","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haibao","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangjian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fuobao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,4,3]]},"reference":[{"key":"57_CR1","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1001\/jama.285.6.785","volume":"285","author":"NIH Consensus Development Panel on Osteoporosis Prevention Diagnosis and Therapy","year":"2001","unstructured":"NIH Consensus Development Panel on Osteoporosis Prevention Diagnosis and Therapy (2001) Osteoporosis prevention, diagnosis, and therapy. JAMA 285:785\u2013795","journal-title":"JAMA"},{"key":"57_CR2","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.bone.2007.05.010","volume":"41","author":"W Gu","year":"2007","unstructured":"Gu W, Rennie KL, Lin X, Wang Y, Yu Z (2007) Differences in bone mineral status between urban and rural Chinese men and women. Bone 41:393\u2013399","journal-title":"Bone"},{"key":"57_CR3","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jocd.2007.05.004","volume":"10","author":"XG Cheng","year":"2007","unstructured":"Cheng XG, Yang DZ, Zhou Q, Zhuo TJ, Zhang HC, Xiang J, Wang HF, Ou PZ, Liu JL, Xu L, Huang GY, Huang QR, Barden HS, Weynand LS, Faulkner KG, Meng XW (2007) Age-related bone mineral density, bone loss rate, prevalence of osteoporosis, and reference database of women at multiple centers in China. J Clin Densitom 10:276\u2013284","journal-title":"J Clin Densitom"},{"key":"57_CR4","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s007740200026","volume":"20","author":"Z Liu","year":"2002","unstructured":"Liu Z, Piao J, Pang L, Qing X, Nan S, Pan Z, Guo Y, Wang X, Li F, Liu J, Cheng X (2002) The diagnostic criteria for primary osteoporosis and the incidence of osteoporosis in China. J Bone Miner Metab 20:181\u2013189","journal-title":"J Bone Miner Metab"},{"key":"57_CR5","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/j.bone.2007.08.005","volume":"41","author":"Silvano Adami","year":"2007","unstructured":"Adami Silvano (2007) Bisphosphonate antifracture efficacy. Bone 41:S8\u2013S15","journal-title":"Bone"},{"key":"57_CR6","unstructured":"Montvale (2001) Fosamax prescribing information. Physicians\u2019 desk reference@, 55th edn. Medical Economics Co, New Jersey"},{"key":"57_CR7","first-page":"50","volume":"18","author":"T Mersfelder","year":"1999","unstructured":"Mersfelder T, Armitstead JA, Ivey MF, Cedars M (1999) A medication use evaluation of alendronate: compliance with administration guidelines. Pharm Pract Manag Q 18:50\u201358","journal-title":"Pharm Pract Manag Q"},{"key":"57_CR8","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.maturitas.2003.12.012","volume":"48","author":"D Kendler","year":"2004","unstructured":"Kendler D, Kung AW, Fuleihan G-H, Gonz\u00e1lez Gonz\u00e1lez JG, Gaines KA, Verbruggen N (2004) Patients with osteoporosis prefer once weekly to once daily dosing with alendronate. Maturitas 48:243\u2013251","journal-title":"Maturitas"},{"key":"57_CR9","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1016\/S0149-2918(02)80085-6","volume":"24","author":"JA Simon","year":"2002","unstructured":"Simon JA, Lewiecki EM, Smith ME, Petruschke RA, Wang L, Palmisano JJ (2002) Patient preference for once-weekly alendronate 70\u00a0mg versus once-daily alendronate 10\u00a0mg: a multicenter, randomized, open-label, crossover study. Clin Ther 24:1871\u20131886","journal-title":"Clin Ther"},{"key":"57_CR10","doi-asserted-by":"crossref","unstructured":"Rizzoli R, Greenspan SL, Bone G 3rd, Schnitzer TJ, Watts NB, Adami S, Foldes AJ, Roux C, Levine MA, Uebelhart B, Santora AC 2nd, Kaur A, Peverly CA, Orloff JJ, Alendronate Once-Weekly Study Group (2002) Two-year results of once-weekly administration of alendronate 70\u00a0mg for the treatment of postmenopausal osteoporosis. J Bone Miner Res 17:1988\u20131996","DOI":"10.1359\/jbmr.2002.17.11.1988"},{"key":"57_CR11","first-page":"1","volume":"12","author":"T Schnitzer","year":"2000","unstructured":"Schnitzer T, Bone HG, Crepaldi G, Adami S, McClung M et al (2000) Therapeutic equivalence of alendronate 70\u00a0mg once-weekly and alendronate 10\u00a0mg daily in the treatment of osteoporosis. Aging (Milano) 12:1\u201312","journal-title":"Aging (Milano)"},{"key":"57_CR12","first-page":"306","volume":"24","author":"ZQ Cheng","year":"2002","unstructured":"Cheng ZQ, Yin W, Fan JY, Ma TY (2002) The efficacy of alendronate in the prevention and treatment of postmenopausal osteoporosis. Acta Acad Med Sinica 24:306\u2013309","journal-title":"Acta Acad Med Sinica"},{"key":"57_CR13","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S1543-5946(05)80019-4","volume":"3","author":"B Cryer","year":"2005","unstructured":"Cryer B, Binkley N, Simonelli C, Lewiecki EM, Lanza F, Chen E, Petruschke RA, Mullen C, de Papp AE (2005) A randomized, placebo-controlled, 6-month study of once-weekly alendronate oral solution for postmenopausal osteoporosis. Am J Geriatr Pharmacother 3:127\u2013136","journal-title":"Am J Geriatr Pharmacother"},{"key":"57_CR14","unstructured":"National Osteoporosis Foundation (2003) Physician\u2019s guide to prevention and treatment of osteoporosis [Online]. Available at: http:\/\/www.nof.org\/_vti_bin\/shtml.dll\/physguide\/index. htm"},{"key":"57_CR15","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/S8756-3282(01)00676-7","volume":"30","author":"L Yan","year":"2002","unstructured":"Yan L, Prentice A, Zhou B, Zhang H, Wang X, Stirling DM, Laidlaw A, Han Y, Laskey A (2002) Age- and gender-related differences in bone mineral status and biochemical markers of bone metabolism in Northern Chinese men and women. Bone 30:412\u2013415","journal-title":"Bone"},{"key":"57_CR16","first-page":"511","volume":"13","author":"Y Liu","year":"2002","unstructured":"Liu Y, Fan JY (2002) Measuranents of osteocalcin and cross-linked N-telopeptide of type I collagen in postmenopausal osteoporosis. J Tianjin Med Univ 13:511\u2013516","journal-title":"J Tianjin Med Univ"},{"key":"57_CR17","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s00774-005-0616-5","volume":"23","author":"S Uchida","year":"2005","unstructured":"Uchida S, Taniguchi T, Shimizu T, Kakikawa T, Okuyama K, Okaniwa M, Arizono H, Nagata K, Santora AC, Shiraki M, Fukunaga M, Tomomitsu T, Ohashi Y, Nakamura T (2005) Therapeutic effects of alendronate 35\u00a0mg once weekly and 5\u00a0mg once daily in Japanese patients with osteoporosis: a double-blind, randomized study. J Bone Miner Metab 23:382\u2013388","journal-title":"J Bone Miner Metab"},{"key":"57_CR18","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1345\/aph.1E580","volume":"39","author":"AY Ho","year":"2005","unstructured":"Ho AY, Kung AW (2005) Efficacy and tolerability of alendronate once-weekly in Asian postmenopausal osteoporotic women. Ann Pharmacother 39:1428\u20131433","journal-title":"Ann Pharmacother"},{"key":"57_CR19","doi-asserted-by":"crossref","unstructured":"Rosen CJ, Hochberg MC, Bonnick SL, McClung M, Miller P, Broy S, Kagan R, Chen E, Petruschke RA, Thompson DE, de Papp AE; Fosamax Actonel Comparison Trial Investigators (2004) Treatment with once-weekly alendronate 70\u00a0mg compared to once-weekly risedronate 35\u00a0mg in women with postmenopausal osteoporosis: a randomized, double-blind study. J Bone Miner Res 20: 141\u2013151","DOI":"10.1359\/JBMR.040920"},{"key":"57_CR20","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/01.GME.0000119981.77837.1F","volume":"11","author":"M Luckey","year":"2004","unstructured":"Luckey M, Kagan R, Greenspan S, Bone H, Kiel RD, Simon J, Sackarowitz J, Palmisano J, Chen E, Petruschke RA, de Papp AE (2004) Once-weekly alendronate 70\u00a0mg and raloxifene 60\u00a0mg daily in the treatment of postmenopausal osteoporosis. Menopause 11:405\u2013415","journal-title":"Menopause"},{"key":"57_CR21","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.maturitas.2008.05.003","volume":"60","author":"Hee-Jeong Choi","year":"2008","unstructured":"Choi Hee-Jeong, Imb Jee-Aee, Kim Sang-Hwan (2008) Changes in bone markers after once-weekly low-dose alendronate in postmenopausal women with moderate bone loss. Maturitas 60:170\u2013176","journal-title":"Maturitas"},{"key":"57_CR22","doi-asserted-by":"crossref","unstructured":"Hochberg MC, Ross PD, Black D, Fracture Intervention Trial Research Group. (1999) Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Arthritis Rheum 42:1246\u20131254","DOI":"10.1002\/1529-0131(199906)42:6<1246::AID-ANR22>3.0.CO;2-U"},{"key":"57_CR23","first-page":"S144","volume":"15","author":"SR Cummings","year":"2000","unstructured":"Cummings SR, Palermo L, Ensrud KE (2000) Are nonresponders responding? Presented at the Annual Meeting of the American Society of Bone and Mineral Research. J Bone Miner Res 15:S144","journal-title":"J Bone Miner Res"},{"key":"57_CR24","doi-asserted-by":"crossref","unstructured":"Granney A, Guyatt G, Griffith L, Wells G, Tugwell P, Rosen C; Osteoporosis Methodology Group and the Osteoporosis Research Advisory Group (2002) Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 23: 570\u2013578","DOI":"10.1210\/er.2001-9002"},{"key":"57_CR25","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s001980200052","volume":"13","author":"JA Kanis","year":"2002","unstructured":"Kanis JA, Oden A, Johnell O, Caulin F, Bone H, Alexandre JM, Abadie E, Lekkerkerker F (2002) Uncertain future of trials in osteoporosis. Osteoporos Int 13:443\u2013449","journal-title":"Osteoporos Int"},{"issue":"Suppl 3","key":"57_CR26","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1007\/s00198-002-1345-4","volume":"14","author":"P Ammann","year":"2003","unstructured":"Ammann P, Rizzoli R (2003) Bone strength and its determinants. Osteoporos Int 14(Suppl 3):S13\u2013S18","journal-title":"Osteoporos Int"},{"key":"57_CR27","doi-asserted-by":"crossref","unstructured":"Chestnut CH III, Rosen CJ, for the Bone Quality Discussion Group (2001) Reconsidering the effects of antiresorptive therapies in reducing osteoporotic fracture. J Bone Miner Res 16:2163\u20132172","DOI":"10.1359\/jbmr.2001.16.12.2163"},{"key":"57_CR28","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0002-9343(01)01124-X","volume":"12","author":"ST Cummings","year":"2002","unstructured":"Cummings ST, Karpf DB, Harris F, Genant HK, Ensurd K, LaCroix AZ (2002) Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with anti-resorptive drugs. Am J Med 12:281\u2013289","journal-title":"Am J Med"},{"key":"57_CR29","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1210\/jcem.85.1.6267","volume":"85","author":"RD Wasnich","year":"2000","unstructured":"Wasnich RD, Miller PD (2000) Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab 85:231\u2013236","journal-title":"J Clin Endocrinol Metab"},{"key":"57_CR30","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1210\/jcem.87.4.8415","volume":"87","author":"MC Hochberg","year":"2002","unstructured":"Hochberg MC, Greensapn S, Wasnich RD, Miller P, Thompson DE, Ross PD (2002) Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 87:1586\u20131592","journal-title":"J Clin Endocrinol Metab"},{"key":"57_CR31","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1359\/JBMR.0301244","volume":"19","author":"P Gerdhem","year":"2004","unstructured":"Gerdhem P, Ivaska KK, Alatalo SL, Halleen JM, Hellman J, Isaksson A, Pettersson K, V\u00e4\u00e4n\u00e4nen HK, Akesson K, Obrant KJ (2004) Biochemical markers of bone metabolism and prediction of fracture in elderly women. J Bone Miner Res 19:386\u2013393","journal-title":"J Bone Miner Res"},{"key":"57_CR32","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1359\/JBMR.0301243","volume":"19","author":"S Sarkar","year":"2004","unstructured":"Sarkar S, Reginster JY, Crans GG, Diez-Perez A, Pinette KV, Delmas PD (2004) Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk. J Bone Miner Res 19:394\u2013401","journal-title":"J Bone Miner Res"},{"key":"57_CR33","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1002\/jbmr.5650111021","volume":"11","author":"P Garnero","year":"1996","unstructured":"Garnero P, Hausherr E, Chapuy MC, Marcelli C, Grandjean H, Muller C, Cormier C, Br\u00e9art G, Meunier PJ, Delmas PD (1996) Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. J Bone Miner Res 11:1531\u20131538","journal-title":"J Bone Miner Res"},{"key":"57_CR34","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1359\/jbmr.2003.18.6.1051","volume":"18","author":"R Eastell","year":"2003","unstructured":"Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas PD (2003) Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 18:1051\u20131056","journal-title":"J Bone Miner Res"},{"key":"57_CR35","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1007\/s001980170020","volume":"12","author":"NH Bjarnason","year":"2001","unstructured":"Bjarnason NH, Sarkar S, Duong T, Mitlak B, Delmas PD, Christiansen C (2001) Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3\u00a0years of raloxifene treatment in postmenopausal osteoporosis. Osteoporos Int 12:922\u2013930","journal-title":"Osteoporos Int"}],"container-title":["Journal of Bone and Mineral Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-009-0057-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00774-009-0057-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-009-0057-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T02:14:24Z","timestamp":1559096064000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00774-009-0057-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4,3]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,7]]}},"alternative-id":["57"],"URL":"https:\/\/doi.org\/10.1007\/s00774-009-0057-7","relation":{},"ISSN":["0914-8779","1435-5604"],"issn-type":[{"value":"0914-8779","type":"print"},{"value":"1435-5604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,4,3]]}}}